The support of human genetic evidence for approved drug indications
By Matthew R. Nelson, H. Tipney, Jeffery L. Painter, Judong Shen, P. Nicoletti, Yufeng Shen, A. Floratos, Pak Chung Sham, Mulin Jun Li, Junwen Wang and 6 more. Nature Genetics, 2015
1,489 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Genetics, Pharmacology
View Paper: https://www.semanticscholar.org/paper/2e04c244655279fc1e86f641bf13b80b8060c6fb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- Kexin Huang
- Michael M. Bronstein
- Jian Tang
- J. Sáez-Rodríguez
- Michael P. Menden
- Antonio Julià
- Mathew Garnett
- Jure Leskovec
In Genetics
- George Davey Smith
- Gibran Hemani
- Alkes L Price
- Frank Dudbridge
- Stephen Burgess
- Peter M. Visscher
- J. Bowden
- Jian Yang
In Pharmacology
- Michael P. Menden
- Jure Leskovec
- Randy L. Buckner
- Alessandro Serretti
- Arian Jamasb
- Douglas F. Levinson
- Ted G. Dinan
- Kexin Huang
Citations in the corpus
- Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians (2018, neutral): “65 66”
- Evaluating potential drug targets through human loss-of-function genetic variation (2019, background): “The lack of a known pLoF phenotype may arise for multiple reasons: (1) disruption of the gene may cause no discernible phenotype at all; (2) disruption may cause a phenotype that is evolutionarily deleterious but clinically mild, has effects only on reproductive fitness rather than individual health”
- Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. (2017, background): “In support, drug targets with underlying human genetic support are twice as likely to be ultimately approved compared to drug targets without underlying human support.(197)”
- Evaluating drug targets through human loss-of-function genetic variation (2019, positive): “Candidates targeting genes with human genetic evidence for disease causality are more likely to reach approval 3,4 , and identification of humans with loss-of-function (LoF) variants, particularly two-hit (homozygous or compound heterozygous) genotypes, has, for several genes, correctly predicted…”
- 10 Years of GWAS Discovery: Biology, Function, and Translation. (2017, background): “In general, drug targets that are genetically informed have a higher probability of making it to phase III trial or to market, implying potential huge cost savings to the pharmaceutical industry.(72)”
- Genomic dissection of bipolar disorder and schizophrenia including 28 subphenotypes (2018, background): “Further, there is a clear relationship between GWAS results of a phenotype and gene targets of drugs that treat that phenotype, pointing to the potential for improved therapeutic understanding (Nelson et al., 2015; Ruderfer et al., 2016).”